Phase 4 COPD Trial, Recruiting NCT06825013 Sponsor: Dr. J. Alberto Neder Condition: COPD
Back to Copd

Phase 4 COPD Trial, Recruiting

NCT06825013
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with COPD (chronic obstructive pulmonary disease)
  • People aged 40 years or older, male or female
  • People who currently smoke or used to smoke, with a history of at least 20 pack-years (for example, one pack per day for 20 years, or two packs per day for 10 years)
  • People whose breathing test results show a reduced ratio of air blown out quickly compared to total air capacity, falling below the normal range
  • People whose total lung capacity on a breathing test increases by at least 10% after inhaling a reliever medication called salbutamol
  • People whose resting lung air volume is higher than normal (at least 120% of what is expected, or above the upper limit of normal)
  • People who experience at least a moderate level of breathlessness in daily life, as measured by a standard scale called the Modified Medical Research Council dyspnea scale (score of 2 or higher)
  • People who have been medically stable, with no flare-ups of their COPD in the six weeks before joining
  • People who are able to give informed consent and complete all study procedures

Who may not be able to join:

  • People who have significant heart or lung conditions other than COPD, such as asthma, scarring of the lungs, high blood pressure in the lungs, or heart failure
  • People who have diseases affecting their muscles or bones
  • People who need oxygen during the day, or whose oxygen levels drop very low (below 80%) during exercise when breathing normal room air
  • People who have any other condition that could cause breathlessness or difficulty exercising
  • People who have any medical reason that makes exercise testing unsafe or unsuitable for them

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: J Alberto Neder, MD, PhD, Queen's University

Phone: 800-985-8891

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Dr. J. Alberto Neder
Registry
ClinicalTrials.gov
Start date
10 November 2024
Est. completion
1 January 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Airway resistance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov